Online supplementary Table S3

Table S3. $AUC_{0\text{-}inf}$ and $C_{max}1$ in the GP2013, RTX-US and RTX-EU treatment arms using the PK Analysis Set, based on ADA status: including ADA+ patients, excluding ADA+ patients and analyzing ADA+ patient only. Patients with confirmed ADAs at any time up to week 24 for considered for $AUC_{0\text{-}inf}$ analysis and patients with pre-treatment* ADAs were considered for the analysis of $C_{max}1$.

PK parameter (unit)	Treatment	N Including ADA	Adj. geom. mean	N Excluding ADA	Adj. geom. mean	N ADA+ only	Adj. geom. mean
$AUC_{0\text{-}inf}$ (day*mcg/mL)	GP2013	124	7627.44	113	7943.29	11	5027.51
	RTX-US	80	7536.89	72	7808.09	8	5483.02
	RTX-EU	79	6896.97	72	7045.63	7	5538.58
PK parameter (unit)	**Treatment**	**N Including ADA**	**Adj. geom. mean**	**N Excluding ADA**	**Adj. geom. mean**	**N pre-treatment ADA+ only**	**Adj. geom. mean**
C_{max} 1st inf. (mcg/mL)	GP2013	120	361.53	120	361.53	0	NA
	RTX-US	82	335.88	73	332.92	3	424.14
	RTX-EU	78	319.80	72	316.63	1	688.50

* Since it usually takes more than two weeks to develop ADAs, and often longer, the presence of ADA is not expected to affect maximum serum concentration of the first infusion (Cmax1) significantly. Therefore, only pre-treatment ADA+ patients were excluded from Cmax1 analysis.